Antonelli E, Villanacci V, Bassotti G. Novel oral-targeted therapies for mucosal healing in ulcerative colitis. World J Gastroenterol 2018; 24(47): 5322-5330 [PMID: 30598577 DOI: 10.3748/wjg.v24.i47.5322]
Corresponding Author of This Article
Gabrio Bassotti, MD, PhD, Associate Professor, Department of Medicine, Gastroenterology and Hepatology Section, University of Perugia Medical School, Piazza Lucio Severi, San Sisto (Perugia) 06132, Italy. gabassot@tin.it
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Elisabetta Antonelli, Gastroenterology Section, Perugia General Hospital, San Sisto (Perugia) 06156, Italy
Vincenzo Villanacci, Pathology Unit, ASST Spedali Civili, Brescia 25100, Italy
Gabrio Bassotti, Department of Medicine, Gastroenterology and Hepatology Section, University of Perugia Medical School, San Sisto (Perugia) 06132, Italy
Author contributions: Antonelli E and Bassotti G conceived the study and wrote the first draft of the manuscript; Villanacci V gave important intellectual contribution and critically reviewed the manuscript; all authors reviewed and approved the final version of the manuscript.
Conflict-of-interest statement: No conflict of interest exists.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author to: Gabrio Bassotti, MD, PhD, Associate Professor, Department of Medicine, Gastroenterology and Hepatology Section, University of Perugia Medical School, Piazza Lucio Severi, San Sisto (Perugia) 06132, Italy. gabassot@tin.it
Telephone: +39-075-5784423 Fax: +39-075-5847570
Received: September 27, 2018 Peer-review started: September 27, 2018 First decision: October 26, 2018 Revised: November 14, 2018 Accepted: November 16, 2018 Article in press: November 16, 2018 Published online: December 21, 2018
Abstract
Ulcerative colitis (UC), a chronic, relapsing, remitting disease of the colon and rectum, is characterized by inflammatory ulceration of the mucosa. Current UC therapy relies on controlling acute episodes and preventing relapse. To predict modifications in the natural course of UC, mucosal healing (MH) has emerged as a major treatment goal. Endoscopic evaluation is considered the gold standard for assessing MH, which can be achieved by conventional drugs and biologics in many, but not all, patients. Consequently, interest is focusing on the development of new substances for UC therapy, and new oral agents are in the pipeline. This review will focus on the ability of newly developed oral drugs to induce and maintain MH in UC patients.
Core tip: The disease activity of ulcerative colitis (UC) is not sufficiently controlled in a subgroup of patients under the current therapeutic regimens. New oral substances are in the pipeline for treating UC. Mucosal healing (MH) has emerged as an important predictor of modifications in the natural disease course of UC. This review describes the efficacy of new oral drugs in inducing and maintaining MH in UC.
